Latest Attention-deficit hyperactivity disorder controversies Stories
NEW YORK, Aug. 23 /PRNewswire/ -- A new ADD/ADHD study found that a multi-modal hemispheric based program significantly improved the participant's educational outcomes.
Nearly 1 million children in the United States are potentially misdiagnosed with attention deficit hyperactivity disorder simply because they are the youngest â€“ and most immature â€“ in their kindergarten class.
Rising rates of attention deficit hyperactivity disorder (ADHD) and large differences in diagnosis rates have led to fears that the condition is often being misdiagnosed.
A new study led by a team of Boston University School of Public Health researchers suggests a link between polyfluoroalkyl chemicals (PFCs), industrial compounds which are widely used in many consumer products, and attention deficit hyperactivity disorder (ADHD) in children.
DUBLIN and PHILADELPHIA, July 6 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of DaytranaÂ® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years.
A new study published online in the Journal of Pediatrics suggests that neither attention deficit hyperactivity disorder (ADHD) nor medications used to treat it have a long-term impact on kids' growth.
A major study of more than a million children has found strong links between receiving medication for attention deficit hyperactivity disorder (ADHD) and limited maternal education, single parent families and welfare benefits.
NEW ORLEANS, May 25 /PRNewswire/ -- Turning in assignments, following instructions and focusing on learning something new are among the daily classroom challenges for children with Attention Deficit Hyperactivity Disorder (ADHD),(1) according to the National Institute of Mental Health (NIMH).
NEW ORLEANS, May 21 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced new findings on once-daily INTUNIV(TM) (guanfacine) Extended Release Tablets, the first selective alpha-2A agonist approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), at a major psychiatric meeting.
A team of scientists from the University of Montreal and Harvard University have discovered that exposure to organophosphate pesticides is associated with increased risk of Attention-Deficit Hyperactivity Disorder (ADHD) in children.
- Withering but not falling off, as a blossom that persists on a twig after flowering.